Ibere Pharmaceuticals Net Income

Ibere Pharmaceuticals (IBER) currently reports a net income of $13M as of September 2022. That is below the sector sector average of $130M. Use the charts on this page to explore Ibere Pharmaceuticals's net income history and peer comparisons.

Ibere Pharmaceuticals's net income of $13M is lower than the its sector sector average of $130M. That is roughly 89.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Ibere Pharmaceuticals reported $13M in net income as of September 2022. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $13M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $130M. From there, open related valuation or income-statement pages for Ibere Pharmaceuticals, and consider following IBER for alerts when major investors trade the stock.